---
figid: PMC5398990__13311_2017_518_Fig3_HTML
figtitle: Schematic overview of underlying pathophysiology and targeted therapies
  in neurofibromatosis 1 (NF1)-associated malignant peripheral nerve sheath tumors
  (MPNSTs)
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC5398990
filename: 13311_2017_518_Fig3_HTML.jpg
figlink: /pmc/articles/PMC5398990/figure/Fig3/
number: F3
caption: Schematic overview of underlying pathophysiology and targeted therapies in
  neurofibromatosis 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNSTs).
  MPNSTs arise from plexiform neurofibromas (pNFs) via a stepwise malignant transformation
  process that includes the loss of NF1 (gray box), deletion of CDKN2A, and loss of
  TP53 and PRC2. The hyperactivation of the Ras pathway and acquired epigenetic alterations
  provide therapeutic targets for various molecule inhibitors (yellow boxes) GPCR
  = G-protein coupled receptor; RTK = receptor tyrosine kinase; HSP = heat shock protein;
  MEK = mitogen-activated protein kinase; ERK = extracelluar regulated kinase; PI3K
  = phosphatidylinositol 3-kinase; AKT = protein kinase B; mTOR = mammalian target
  of rapamycin; AURKA = Aurora kinase A; BET = bromodomain and extraterminal; PRC2
  = polycomb repressive complex 2; aNF = atypical neurofibroma; pNF = plexiform neurofibroma
papertitle: Cancer of the Peripheral Nerve in Neurofibromatosis Type 1.
reftext: Verena Staedtke, et al. Neurotherapeutics. 2017 Apr;14(2):298-306.
year: '2017'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9617926
figid_alias: PMC5398990__F3
figtype: Figure
redirect_from: /figures/PMC5398990__F3
ndex: 0fb604eb-dec2-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5398990__13311_2017_518_Fig3_HTML.html
  '@type': Dataset
  description: Schematic overview of underlying pathophysiology and targeted therapies
    in neurofibromatosis 1 (NF1)-associated malignant peripheral nerve sheath tumors
    (MPNSTs). MPNSTs arise from plexiform neurofibromas (pNFs) via a stepwise malignant
    transformation process that includes the loss of NF1 (gray box), deletion of CDKN2A,
    and loss of TP53 and PRC2. The hyperactivation of the Ras pathway and acquired
    epigenetic alterations provide therapeutic targets for various molecule inhibitors
    (yellow boxes) GPCR = G-protein coupled receptor; RTK = receptor tyrosine kinase;
    HSP = heat shock protein; MEK = mitogen-activated protein kinase; ERK = extracelluar
    regulated kinase; PI3K = phosphatidylinositol 3-kinase; AKT = protein kinase B;
    mTOR = mammalian target of rapamycin; AURKA = Aurora kinase A; BET = bromodomain
    and extraterminal; PRC2 = polycomb repressive complex 2; aNF = atypical neurofibroma;
    pNF = plexiform neurofibroma
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Tie
  - Ras85D
  - InR
  - Oamb
  - Nf1
  - ras
  - Ras64B
  - Raf
  - Akt
  - Dsor1
  - Mtk
  - Mtor
  - Tor
  - Erk7
  - rl
  - aurA
  - bet
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - mid
  - FZD4
  - NMUR1
  - LPAR3
  - LGR6
  - MRGPRX3
  - MRGPRX4
  - GPR151
  - OXER1
  - GPRC6A
  - MRGPRX1
  - VN1R17P
  - GPR166P
  - GRM1
  - GRM2
  - GRM3
  - GRM4
  - GRM5
  - GRM6
  - GRM7
  - GRM8
  - CASR
  - GABBR1
  - GABBR2
  - GPR156
  - GPR158
  - GPR179
  - GPRC5A
  - GPRC5B
  - GPRC5C
  - GPRC5D
  - HSP90B2P
  - NF1
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MTOR
  - EPHB2
  - MAPK1
  - MAPK3
  - AURKA
  - DNER
  - NPPA
  - HESX1
  - TP53
  - CDKN2A
  - EED
  - EZH1
  - EZH2
  - SUZ12
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
